Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CD38 expression
i
Other names:
CD38, CD38 Molecule, ADP-Ribosyl Cyclase 1, ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1, 2'-Phospho-Cyclic-ADP-Ribose Transferase, 2'-Phospho-ADP-Ribosyl Cyclase, Cyclic ADP-Ribose Hydrolase 1, NAD(+) Nucleosidase, CD38 Antigen (P45), ADPRC 1, 2'-Phospho-ADP-Ribosyl Cyclase/2'-Phospho-Cyclic-ADP-Ribose Transferase, Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase, Cluster Of Differentiation 38, CADPr Hydrolase 1, CD38 Antigen, ADPRC1, T10
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
952
Related biomarkers:
Expression
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
CD38 expression
Multiple Myeloma
CD38 expression
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
CD38 expression
Lymphoma
CD38 expression
Lymphoma
rituximab + NKTR-255
Sensitive: C3 – Early Trials
rituximab + NKTR-255
Sensitive
:
C3
rituximab + NKTR-255
Sensitive: C3 – Early Trials
rituximab + NKTR-255
Sensitive
:
C3
CD38 expression
Waldenstrom Macroglobulinemia
CD38 expression
Waldenstrom Macroglobulinemia
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
CD38 expression
Lymphoma
CD38 expression
Lymphoma
daratumumab + NKTR-255
Sensitive: C3 – Early Trials
daratumumab + NKTR-255
Sensitive
:
C3
daratumumab + NKTR-255
Sensitive: C3 – Early Trials
daratumumab + NKTR-255
Sensitive
:
C3
CD38 expression
Multiple Myeloma
CD38 expression
Multiple Myeloma
BHV-1100
Sensitive: C3 – Early Trials
BHV-1100
Sensitive
:
C3
BHV-1100
Sensitive: C3 – Early Trials
BHV-1100
Sensitive
:
C3
CD38 expression
Triple Negative Breast Cancer
CD38 expression
Triple Negative Breast Cancer
durvalumab
Sensitive: C3 – Early Trials
durvalumab
Sensitive
:
C3
durvalumab
Sensitive: C3 – Early Trials
durvalumab
Sensitive
:
C3
CD38 expression
Multiple Myeloma
CD38 expression
Multiple Myeloma
STI-6129
Sensitive: D – Preclinical
STI-6129
Sensitive
:
D
STI-6129
Sensitive: D – Preclinical
STI-6129
Sensitive
:
D
CD38 expression
Multiple Myeloma
CD38 expression
Multiple Myeloma
SAR442257
Sensitive: D – Preclinical
SAR442257
Sensitive
:
D
SAR442257
Sensitive: D – Preclinical
SAR442257
Sensitive
:
D
CD38 expression
Multiple Myeloma
CD38 expression
Multiple Myeloma
SAR442085
Sensitive: D – Preclinical
SAR442085
Sensitive
:
D
SAR442085
Sensitive: D – Preclinical
SAR442085
Sensitive
:
D
CD38 expression
Multiple Myeloma
CD38 expression
Multiple Myeloma
TAK-079
Sensitive: D – Preclinical
TAK-079
Sensitive
:
D
TAK-079
Sensitive: D – Preclinical
TAK-079
Sensitive
:
D
CD38 expression
Multiple Myeloma
CD38 expression
Multiple Myeloma
ISB 1342
Sensitive: D – Preclinical
ISB 1342
Sensitive
:
D
ISB 1342
Sensitive: D – Preclinical
ISB 1342
Sensitive
:
D
CD38 expression
B Acute Lymphoblastic Leukemia
CD38 expression
B Acute Lymphoblastic Leukemia
isatuximab-irfc
Sensitive: D – Preclinical
isatuximab-irfc
Sensitive
:
D
isatuximab-irfc
Sensitive: D – Preclinical
isatuximab-irfc
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.